Pine Bark Extract (Pycnogenol): What the Research Actually Shows

By Erin Rose · Updated July 19, 2026 · Methodology

Educational overview — not medical advice. Pine bark extract has a mechanistic, unconfirmed-in-humans antiplatelet caution; talk to your clinician before combining it with blood thinners or before surgery. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

As an Amazon Associate we earn from qualifying purchases. On best pine bark extract, products are split by genuine-Pycnogenol® vs generic first, standardization and cost second — never by commissions.

Start here

What pine bark extract is, and why "Pycnogenol" is really the whole story

Pine bark extract comes from the bark of Pinus pinaster ssp. atlantica, the French maritime pine, standardized to oligomeric proanthocyanidins (OPCs) — the same class of compound as grape seed extract. It has a large body of human trials, but that body is overwhelmingly dominated by one single patented, branded ingredient: Pycnogenol®, owned and licensed by Horphag Research. A meaningful share of the positive trials were authored or co-authored by Peter Rohdewald — the chemist who patented and developed Pycnogenol — or by Horphag Research employees, or run by one small, extremely prolific Italian research group (Cesarone, Belcaro, and colleagues at the San Valentino Vascular Screening Project) whose papers recur across nearly every condition Pycnogenol is marketed for. That concentration matters: Weichmann & Rohdewald 2024, a narrative review of "39 gold standard" Pycnogenol trials, is literally co-authored by a then-Horphag Research employee reviewing their own employer's product — direct, self-disclosed evidence of how industry-concentrated this literature is.

The independent verdict: Cochrane says "insufficient"

The single fully independent evidence-quality anchor for this entire category is Robertson 2020, Cochrane's update of a 2012 review. It pooled 27 RCTs (22 parallel, 5 cross-over), 1,641 participants, across 10 chronic disorders — asthma, ADHD, cardiovascular risk factors, chronic venous insufficiency, diabetes, erectile dysfunction, female sexual dysfunction, osteoarthritis, osteopenia, and traumatic brain injury. Risk of bias was low in only 4 of the 27 trials and unclear in 22. Every single reported effect — diastolic blood pressure, cholesterol change, venous-insufficiency symptom scores, HbA1c, erectile-function scores, osteoarthritis scores — was rated "very low-certainty evidence," almost always from a single small trial per outcome. The authors' own conclusion: "Small sample sizes, limited numbers of RCTs per condition, variation in outcome measures, and poor reporting of the included RCTs mean no definitive conclusions regarding the efficacy or safety of pine bark extract supplements are possible." The authors declared no conflicts of interest. That verdict should anchor the tone of every efficacy claim about pine bark extract, on this site or anywhere else.

Blood pressure: three meta-analyses, three different answers

On the best-studied outcome, blood pressure, three meta-analyses of overlapping trial pools reach three different conclusions. Fogacci 2020 (7 trials, N=626, the strictest inclusion filter) found no significant effect on systolic, diastolic, mean arterial, or pulse pressure. Pourmasoumi 2020 (12 trials, N=922) found a modest significant reduction (SBP −3.22 mmHg, DBP −1.91 mmHg) — but the systolic effect was "more pronounced" when Pycnogenol was combined with other treatments, not as monotherapy. Zhang 2018 (9 trials, N=549) also found a significant pooled reduction, but its own conclusion states plainly: "this significant reduction was not observed in well-designed trials" — the positive pooled result is carried by the lower-quality studies in the pool. That disagreement, not any single number, is the honest state of the blood-pressure evidence — full breakdown on the circulation page.

Where it's relatively better supported: circulation, and the honest limits there too

Chronic venous insufficiency and edema are the relatively better-supported area — a real "phlebotonic" evidence category. But even Cochrane's broader phlebotonics review (Martinez-Zapata 2020, covered on the grape seed extract pages) rates the entire drug class only moderate-certainty at best, and the CVI-specific Pycnogenol trials in this pack (Cesarone 2010, Belcaro 2018) come from that same small, repeatedly-cited Italian research group. An independent, non-industry, NIH-registered RCT out of Stanford (Drieling 2010) tested a different, non-Pycnogenol pine bark extract at 200mg/day for 12 weeks in 130 at-risk adults and found no effect on blood pressure or any other cardiovascular risk factor — "our results are consistent with a general failure of antioxidants to demonstrate cardiovascular benefits." Skin photoaging has one credible independent RCT (Zhao 2021). Diabetes/retinopathy, erectile dysfunction, ADHD, and asthma are each represented by a single small, mostly industry-adjacent trial or the ED combination-product meta-analysis — hedge every one of those claims hard.

Frequently asked questions

Sources

Related guides

• Grape Seed Extract — the sibling OPC extract, with an arguably more independent blood-pressure evidence base
• Does Grape Seed Extract Actually Lower Blood Pressure? — the parallel meta-analysis reckoning
• Citrus Bergamot — another small, industry-adjacent cardiovascular evidence base, for contrast
• CoQ10 — another antioxidant-mechanism cardiovascular supplement with a real industry-funding footprint
• Garlic — a cardiovascular botanical with real but modest BP-lowering meta-analytic evidence

Compare Pine Bark Extract Products by Cost Per Day

If you're ready to buy, here's how the pine bark extract products we track and verify compare on cost per day.